Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) — The “Enzymatic DNA Synthesis Market by Service, by Application, by End-User, and By Region” report has been added to ResearchAndMarkets.com’s offering.
The global enzymatic DNA synthesis market is estimated to be USD 0.296 billion in 2024 and is expected to reach USD 3.90 billion by 2035, with a CAGR of 26.43% during the forecast period 2025-2035.
The market will grow due to factors such as the rising need for eco-friendly and sustainable processes, expanding applications in biotechnology and healthcare, growing demand for synthetic DNA, technological advancements in DNA synthesis, and rising use of DNA-based data storage solutions.
The enzymatic DNA synthesis market plays a crucial role in the healthcare sector, particularly in the development of targeted therapies, diagnostics, and vaccines, including mRNA vaccines.? Biotechnology companies are increasingly utilizing synthetic DNA for advancements in personalized medicine, particularly in areas such as CAR-T cell therapy and gene editing. The enzymatic DNA synthesis approach facilitates rapid production, enabling prompt responses to emerging health threats. In June 2024, Ansa Biotechnologies, Inc., a recognized partner in complex DNA synthesis, announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Notably, Ansa is the only company capable of synthesizing complete, contiguous DNA oligonucleotides up to 600 base pairs in length without the need for assembly, providing products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments.
By service, the oligonucleotide synthesis segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the high demand for oligonucleotides in various research and diagnostic applications, including PCR, qPCR, and next-generation sequencing (NGS), where they serve as essential primers and probes. For instance, Ansa Biotechnologies, Inc., the reliable partner for complicated DNA synthesis, said today that it is growing its early access program for its services in May 2024. More clients worldwide will benefit from the company’s cutting-edge enzymatic DNA synthesis technology, which will spur innovation in life science research, healthcare, and other synthetic DNA-powered industries. Additionally, the gene synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of synthetic genes for applications in synthetic biology, genetic engineering, and therapeutic development, particularly in personalized medicine and gene therapy.
By application, the synthetic biology segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the increasing applications of synthetic biology in industrial biotechnology, agricultural genomics, and healthcare. For instance, in August 2024, Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announced key milestones for therapeutic DNA target accuracy and technology automation for the Defense Advanced Research Projects Agency (DARPA) project called NOW (Nucleic Acids On-Demand Worldwide). Under the direction of GE HealthCare’s Technology and Innovation Center (previously GE Research), a multidisciplinary team is working on this ambitious initiative that aims to make it possible to produce DNA-based vaccinations and treatments anywhere in the globe in a matter of days. Additionally, the vaccine development segment is predicted to grow at the fastest CAGR during the forecast period owing to its critical role in the rapid design and production of DNA-based vaccines, including mRNA and plasmid DNA vaccines.
By end-user, the Biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the extensive use of synthetic DNA in drug discovery, genetic research, and biologics production. For instance, in April 2024, Ginkgo Bioworks (NYSE: DNA), which is developing the industry-leading platform for cell programming and biosecurity, and Prozomix, a UK-based biotech business specializing in the discovery and production of innovative biocatalysts, announced a new collaboration. Ginkgo and Prozomix are working together to expand the manufacturing of next-generation enzyme plates for the production of active pharmaceutical ingredients (APIs). This partnership intends to take advantage of Prozomix’s established enzyme libraries and extensive experience in the production of enzyme plates, as well as Ginkgo’s Enzyme Services and industry-leading AI/ML models. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing outsourcing trend in the pharmaceutical and biotechnology industries, where CROs play a key role in providing DNA synthesis services for preclinical and clinical research.
The North American region is anticipated to have the highest revenue share during the forecast period owing to the established presence of leading biotechnology and pharmaceutical companies, significant investments in genetic research and synthetic biology, and strong support from government initiatives and funding for genomics and DNA synthesis innovations. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of biotechnology and pharmaceutical industries, increasing government support for life sciences research, and growing investments in synthetic biology and gene therapy.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Market Forecast by Service, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Company Profiles of the Top 10+ Major Market Players
- Twist Bioscience
- Codex DNA
- DNA Script
- Ansa Biotechnologies
- GenScript Biotech
- Thermo Fisher Scientific
- Integrated DNA Technologies (IDT)
- Ginkgo Bioworks
- Evonetix
- Synthetic Genomics
- ATUM (formerly DNA2.0)
- OriCiro Genomics
- Nuclera
- SGI-DNA (Synthetic Genomics)
- Telesis Bio
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 – 2034 |
| Estimated Market Value (USD) in 2023 | $0.3 Billion |
| Forecasted Market Value (USD) by 2034 | $3.9 Billion |
| Compound Annual Growth Rate | 26.4% |
| Regions Covered | Global |
Key Topics Covered:
1. Research Methodology
2. Introduction
2.1. Market Definition
2.2. Global Enzymatic DNA Synthesis Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Enzymatic DNA Synthesis Market: Service Estimates & Trend Analysis
7.1. Service Segment Opportunity Analysis
7.2. Oligonucleotide Synthesis
7.3. Gene Synthesis
8. Enzymatic DNA Synthesis Market: Application Estimates & Trend Analysis
8.1. Application Segment Opportunity Analysis
8.2. Synthetic Biology
8.3. Genetic Engineering
8.4. Vaccine Development
8.5. Others
9. Enzymatic DNA Synthesis Market: End-User Estimates & Trend Analysis
9.1. End-User Segment Opportunity Analysis
9.2. Biopharmaceutical Companies
9.3. Academic & Research Institutes
9.4. Contract Research Organizations
10. Regional Market Analysis
11. North America Enzymatic DNA Synthesis Market
12. Europe Global Enzymatic DNA Synthesis Market
13. Asia Pacific Global Enzymatic DNA Synthesis Market
14. Latin America Global Enzymatic DNA Synthesis Market
15. MEA Global Enzymatic DNA Synthesis Market
16. Competitor Analysis
16.1. Company Market Share Analysis, 2024
16.2. Major Recent Developments
17. Company Profiles
- Twist Bioscience
- Codex DNA
- DNA Script
- Ansa Biotechnologies
- GenScript Biotech
- Thermo Fisher Scientific
- Integrated DNA Technologies (IDT)
- Ginkgo Bioworks
- Evonetix
- Synthetic Genomics
- ATUM (formerly DNA2.0)
- OriCiro Genomics
- Nuclera
- SGI-DNA (Synthetic Genomics)
- Telesis Bio
For more information about this report visit https://www.researchandmarkets.com/r/kqrwdi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Enzymatic DNA Synthesis Market
